That's important, due to the fact that the method a protein in the body folds figures out if a pharmaceutical will be able to bind to that protein and be efficient. To put it simply, we need to know how these proteins fold if we desire a drug to work. Historically, this has been an experimental procedure (exponential tech investor). And now, Alpha, Fold can anticipate protein folding with 92. 4% accuracy. That's going to make it much easier to develop drugs that do what they're created to do. This was a development practically nobody observed. But it's going to have profound ramifications for treating disease. I anticipate that Alpha, Fold will be 98% accurate by the end of 2021.
And, obviously, there will be plenty of financial investment chances in this area, too. Shifting subjects It's going to be a good year for bitcoin. I'm bullish on it in 2021 (future report review). That stated, I still believe bitcoin will continue to be unstable. We're close to all-time highs. I wouldn't be amazed if it pulled back perhaps significantly prior to going greater - brownstone research stock. I've been covering bitcoin for a very long time now. One of the first research study reports I ever published was on bitcoin. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
But at the time of that preliminary suggestion, I titled my report "What's the Big Deal With Bitcoin?" That shows you where the discussion was at the time. We were primarily educating readers. But that's not the big concern any longer. Now we're seeing institutional money finally take an interest in bitcoin. Massachusetts Mutual Life Insurance took a $100 million stake in bitcoin in December. This is not some small, niche business. Mass, Mutual is a relied on 170-year-old institution. So think of that. In 5 years, we went from informing readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake.
Which's a big factor I'm bullish on it this year. jeff brown top biotech stock 2021. Regards, Jeff Brown, Editor, The Bleeding Edge I have a perk forecast 2020 was a record year for IPOs. 552 U.S. companies went public the most in more than twenty years. These companies raised a total of $172 billion. That's an all-time high beating the previous yearly record by 43%. I anticipate 2021 will be another record year in IPOs. There are a lot of excellent private business on the edge of hitting the general public markets And I've been dealing with a brand-new method for you to invest even prior to these companies go public.
This opportunity has actually been developing over the last few years. I can't wait to inform you all about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Event to discover out all the details. Go right here to schedule your area totally free.
Emma Walsh here, managing editor of the Journal. Regular Diary readers know that tech isn't our normal beat (diplomatic relations). And when it concerns tech investing, we leave it to the experts. Luckily, we have numerous such specialists in our Rolodex. Our colleague Jeff Brown will be familiar to our longtime readers. He is one of the most accomplished tech investing specialists we understand (jeff bezos). In truth, he had a number of triple-digit returns in his Brownstone Research portfolios in 2015. Here's what Jeff believes the tech sector will bring us in 2021 Each year, I like to have a look at the huge picture and anticipate what's just around the corner.
That includes things like 5G networks, biotech, expert system, and much more. These patterns are experiencing rapid development and producing unbelievable opportunities for financiers. I desire to make certain all our readers are gotten ready for what's next. And with that in mind, let me draw the photo of what I see can be found in the next 12 months Our new 5G (fifth-generation) cordless networks are a topic I have actually been covering for years now. genetic sequencing companies jeff brown. But regardless of what numerous readers may think, this is a trend that's just getting begun. Although the COVID-19 pandemic disrupted supply chains in 2015, an excellent 250 million 5G-enabled gadgets were still sold.
And all of this ultimately resulted in Apple delaying the release of the 5G-enabled i, Phone 12 by two months (last year). Losing two months of production and sales truly impacts the number of 5G gadgets are sold in the fiscal year. When you think about all of that, offering 250 million units is impressive. More significantly, the hold-ups brought on by the pandemic produced a lots of pent-up demand. And that need is now going to be pushed into 2021. In truth, I forecast that more than 500 million 5G gadgets will be delivered in 2021 - jeff brown top biotech stock 2021. Which's not my only 5G forecast When I've spoken about 5G in the past, I've explained its 3 various stages.
In Phase 2, 5G gadgets go on sale. 5G phones and other products begin to reach consumers. And in Phase Three, 5G services start to be provided (exponential tech investor). That's when we begin to see applications operating on 5G networks. Consider things like enormous multiplayer games over a mobile phone. That's not possible with 4G. It will be with 5G. And my second 5G forecast for 2021 is that we will begin Stage Three by this summertime. This begins something of a virtuous cycle: Most people do not really appreciate the innovation. But they will care if there are exciting applications that can only be accessed with a 5G phone.
That leads to more 5G apps being developed. In fact, 5G is going to open up a suite of unbelievable applications: self-driving cars, the Web of Things, robotic surgical treatment, and more. All of these technologies require 5G. The financial investment chances going forward will be massive. Stepping away from 5G, the next crucial technology I predict in 2021 is CRISPR genetic modifying. CRISPR means "clustered regularly interspaced short palindromic repeat." It's a mouthful. But it's one of the most interesting developments in biotechnology. At a high level, CRISPR is an innovation that can edit our genetic makeup as if it were software.
The program can crash or not operate correctly. CRISPR uses a similar idea but with our hereditary code. "Typos" in our genome can cause disease. CRISPR can fix these "typos." For years, CRISPR was mostly a specific niche innovation that wasn't well comprehended. And during that time, there were actually only 3 companies operating in this area. But things are changing. CRISPR is no longer simply theoretical. We're seeing actual outcomes. We're treating diseases and seeing that this innovation just works. And as a result, a "2nd crop" of early-stage CRISPR business is going public and providing unbelievable returns. This whole market is successfully a greenfield opportunity.
There's space for numerous business to exist in this space. jeff brown. And there will be more. That's my prediction for CRISPR in 2021. I predict that 2 or three more hereditary editing business will hold their IPOs. Sticking with biotechnology, we are seeing fantastic things taking place at the convergence of biotech and artificial intelligence (AI). Google's AI subsidiary, Deep, Mind, just revealed at the end of 2020 that its most current Alpha, Fold software application can accurately predict the folding of a protein based exclusively on its amino acid sequence with 92. 4% precision. That is essential since the way a protein in the body folds figures out if a pharmaceutical will be able to bind to that protein and be reliable.
Historically, this has been a trial-and-error procedure. Today, Alpha, Fold can forecast protein folding with 92. 4% accuracy. That's going to make it much easier to produce drugs that do what they're created to do. And here's my next forecast. I predict that Alpha, Fold will be 98% precise by the end of 2021. And we will see not simply one but numerous drug treatments produced utilizing this technology. This was among those advancements that nearly nobody observed. However it's going to have extensive implications for curing disease. And, of course, there will be plenty of investment chances in this area, too.
It's going to be a good year for bitcoin. I'm bullish on it in 2021. That said, I still believe bitcoin will continue to be unpredictable. We're close to all-time highs. I wouldn't be amazed if it drew back perhaps substantially before going greater. I have actually been covering bitcoin for a long time now. Among the very first research study reports I ever released was on bitcoin - second wave. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on financial investment for any person who followed my recommendation. However at the time of that initial suggestion, I titled my report, "What's the Big Deal With Bitcoin?" That reveals you where the conversation was at the time.
But no one is asking that concern any longer. Now, we're seeing institutional money lastly taking an interest in bitcoin. The huge news was that Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some little, specific niche enterprise. artificial intelligence. Mass, Mutual is a 150-year-old institution. So consider that. In 5 years, we went from educating readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. And that's a big reason I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have another benefit forecast In 2021, we're going to have another record year in IPOs. One website reports that Jeff Brown deserves about $27. 5 million and claims the information is up to date as of February 2021, but we might not independently confirm this claim. Given Jeff Brown's past, he likely has a considerable net worth, however we can't hammer down an accurate figure at this minute. Brown is best known for his sage-like ability to pick winning technology stocks. He invested more than 25 years researching technology business like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's substantial experience offers him an excellent point of view on the marketplace. He's always on the hunt for brand-new chances, and he shares much of his finest picks in the Future Report.
That's high praise, but it's not ridiculously reasoned. Brown has an excellent reputation as a stock-picker, and he successfully forecasted some of the biggest economic events of the previous 20 years. Although he does not appear to launch his picks to the general public, the service's success is a direct indicator of Brown's stock-picking expertise. Nobody on Wall Street gets it right each time, but Jeff Brown's precise predictions have actually earned him legions of dedicated fans. That states a lot about his ability. The Future Report is released by Brownstone Research study, a popular financial research study publisher. Brownstone Research offers numerous research services with a large range of specializations - jeff brown stock predictions.
The company is also associated with Bonner & Partners, another well-respected research study publisher - genetic sequencer stock jeff brown. On its website, Brownstone states its mission is to provide retail financiers with professional-grade research: "For too long, the very best financial investment research study has not been readily available to private investors. It has actually been typically scheduled for financial investment banks, hedge funds, private equity, and high-net-worth clients. bleeding edge. The objective of Brownstone Research study is to make that type of proprietary research study offered to any investors seeking to get an edge in the markets. The objective is simple to deliver unique and profitable investment research study discovered no place else." -Brownstone Research site excerpt from the Jeff Brown is the creator of Brownstone Research study, and he also works as the firm's Chief Financial investment Analyst.
With Brown assisting the ship, Brownstone Research study is a powerhouse publisher with lots to provide its customers. After years of consistent success at the helm of top-tier companies like Tesla and Area, X, Elon Musk is a family name throughout the majority of America. If you know even a little bit about the market, you understand that he has a credibility as a King Midas of sorts. biotech stocks. Everything he touches turns to gold! Jeff is well conscious of Elon Musk's executive prowess, so he constantly has an eye out for the Silicon Valley rock star's next move. This time, Jeff has an early lead on Elon's next big task.
In fact, Brown thinks S.A.V. future report. could be "the most significant pattern of the 2020s, and he's not alone. Take a look at these quotes from other widely known S.A.V. bulls: Elon's next big act will be weding two cutting-edge innovations: expert system and electrical vehicles. Musk hopes the mix will help him develop the very first fully-autonomous, self-driving vehicles ever. It's absolutely nothing except the automobile market's Holy Grail. As you understand, electric automobiles and self-driving vehicle stocks have actually been huge this year, but the Wall Street maker has approved hype without much tangible outcome. Despite a drastic boost in competitors over the past couple of years, Brown still believes Musk has the finest possibility of putting it all together.
tech could be the magic string that connects everything together. S.A.V. means Shared Autonomous Automobile, and it could be the future of transport. Essentially, this technology would enable you to lease out your automobile as a self-governing, self-driving taxi when you're not using it. You merely get out of the cars and truck and press a button on an app that informs the automobile to "join the fleet." Next thing you understand, you're unwinding on your couch while your car shuttles ride-sharers around town. Best of all, you get to keep a significant portion of the earnings. It sounds ridiculous, but it might be closed than you think.